Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors

FEBS Letters

Volumn 587, Issue 15, 2013, Pages 2325-2331

  Zanotti, Giuseppe ^a,b   Cendron, Laura ^a,b   Folli, Claudia ^c   Florio, Paola ^c   Imbimbo, Bruno Pietro ^d   Berni, Rodolfo ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d Chiesi Farmaceutici   (Italy)

Author keywords

Amyloidosis; Fibrillogenesis inhibitor; Protein misfolding; Transthyretin; Transthyretin stabilizer

Indexed keywords

CHF 5074; DIFLUNISAL; FLURBIPROFEN; PREALBUMIN; PROTEIN INHIBITOR; PROTEIN VARIANT; UNCLASSIFIED DRUG;

ACIDITY; AMYLOIDOSIS; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG STRUCTURE; IN VITRO STUDY; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STABILITY; X RAY CRYSTALLOGRAPHY;

AMYLOIDOSIS; FIBRILLOGENESIS INHIBITOR; HALOGEN BINDING POCKET; HBP; PDB; PROTEIN DATA BANK; PROTEIN MISFOLDING; T4; THYROXINE; TRANSTHYRETIN; TRANSTHYRETIN STABILIZER; TTR; WILD TYPE-TTR; WT-TTR;

AMYLOID; CRYSTALLOGRAPHY, X-RAY; HYDROGEN-ION CONCENTRATION; MODELS, MOLECULAR; NEUROFIBRILS; PREALBUMIN; PROTEIN CONFORMATION;

EID: 84880700247     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.06.016     Document Type: Article

References (25)

1. F. Chiti, and C.M. Dobson Amyloid formation by globular proteins under native conditions Nat. Chem. Biol. 5 2009 15 22
2. M.B. Pepys Amyloidosis Annu. Rev. Med. 57 2006 223 241
3. S.M. Johnson, R.L. Wiseman, Y. Sekijima, N.S. Green, S.L. Adamski-Werner, and J.W. Kelly Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses Acc. Chem. Res. 38 2005 911 921
4. S. Connelly, S. Choi, S.M. Johnson, J.W. Kelly, and I.A. Wilson Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses Curr. Opin. Struct. Biol. 20 2010 54 62
5. S.M. Johnson, S. Connelly, C. Fearns, E.T. Powers, and J.W. Kelly The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug J. Mol. Biol. 421 2012 185 203
6. A. Hornberg, T. Eneqvist, A. Olofsson, E. Lundgren, and A.E. Sauer-Eriksson A comparative analysis of 23 structures of the amyloidogenic protein transthyretin J. Mol. Biol. 302 2000 649 669
7. N. Pasquato, R. Berni, C. Folli, B. Alfieri, L. Cendron, and G. Zanotti Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin J. Mol. Biol. 366 2007 711 719
8. L. Cendron, A. Trovato, F. Seno, C. Folli, B. Alfieri, G. Zanotti, and R. Berni Amyloidogenic potential of transthyretin variants: insights from structural and computational analyses J. Biol. Chem. 284 2009 25832 25841
9. S.K. Palaninathan, N.N. Mohamedmohaideen, W.C. Snee, J.W. Kelly, and J.C. Sacchettini Structural insight into pH-induced conformational changes within the native human transthyretin tetramer J. Mol. Biol. 382 2008 1157 1167
10. W. Colon, and J.W. Kelly Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro Biochemistry 31 1992 8654 8660
11. I. Peretto, S. Radaelli, C. Parini, M. Zandi, L.F. Raveglia, G. Dondio, L. Fontanella, P. Misiano, C. Bigogno, A. Rizzi, B. Riccardi, M. Biscaioli, S. Marchetti, P. Puccini, S. Catinella, I. Rondelli, V. Cenacchi, P.T. Bolzoni, P. Caruso, G. Villetti, F. Facchinetti, E. Del Giudice, N. Moretto, and B.P. Imbimbo Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion J. Med. Chem. 48 2005 5705 5720
12. S.R. Miller, Y. Sekijima, and J.W. Kelly Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants Lab. Invest. 84 2004 545 552
13. A.G.W. Leslie The integration of macromolecular diffraction data Acta Crystallogr. D Biol. Crystallogr. 62 2006 48 57
14. P. Evans Scaling and assessment of data quality Acta Crystallogr. D Biol. Crystallogr. 62 2006 72 82
15. Collaborative Computational Project, Number 4 The CCP4 suite: programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 50 1994 760 763
16. P.D. Adams, P.V. Afonine, G. Bunkoczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, A.J. McCoy, N.W. Moriarty, R. Oeffner, R.J. Read, D.C. Richardson, J.S. Richardson, T.C. Terwilliger, and P.H. Zwart PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D Biol. Crystallogr. 66 2010 213 221
17. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. Sect. D-Biol. Crystallogr. 53 1997 240 255
18. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr. Sect. D-Biol. Crystallogr. 60 2004 2126 2132
19. J. Painter, and E.A. Merritt Optimal description of a protein structure in terms of multiple groups undergoing TLS motion Acta Crystallogr. D Biol. Crystallogr. 62 2006 439 450
20. J.L. Berk, O.B. Suhr, Y. Sekijima, T. Yamashita, M. Heneghan, S.R. Zeldenrust, Y. Ando, S. Ikeda, P. Gorevic, G. Merlini, J.W. Kelly, M. Skinner, A.B. Bisbee, P.J. Dyck, L. Obici Familial Amyloidosis Consortium The Diflunisal Trial: study accrual and drug tolerance Amyloid 19 Suppl. 1 2012 37 38
21. A. Wojtczak, V. Cody, J.R. Luft, and W. Pangborn Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3′,5′-dinitro-N-acetyl-L-thyronine at 2.2 A resolution Acta Crystallogr. D Biol. Crystallogr. 52 1996 758 765
22. T. Klabunde, H.M. Petrassi, V.B. Oza, P. Raman, J.W. Kelly, and J.C. Sacchettini Rational design of potent human transthyretin amyloid disease inhibitors Nat. Struct. Biol. 7 2000 312 321
23. S.L. Adamski-Werner, S.K. Palaninathan, J.C. Sacchettini, and J.W. Kelly Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis J. Med. Chem. 47 2004 355 374
24. 2+-binding sites in human transthyretin: implications for amyloidogenesis and retinol-binding protein recognition J. Biol. Chem. 285 2010 31731 31741
25. L.M. Lima, V.D. Silva, L.D. Palmieri, M.C. Oliveira, D. Foguel, and I. Polikarpov Identification of a novel ligand binding motif in the transthyretin channel Bioorog. Med. Chem. 18 2010 100 110